BIIB (74) ARGX (63) BNTX (52) MRNA (60) ⌘ Pro Terminal →

Revolution Medicines Inc. (RVMD) — RQD Stock Rating Cockpit

$190.27 +0.82% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Revolution Medicines Inc. (RVMD) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $40.78B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE-1.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RVMD)Realized 20D OHLCV Swing Band: ±10.1%

RSI-14 MOMENTUMNEUTRAL RANGE

47.830 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

26.00>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

5 / 99-Pt Accounting

52-WEEK LASER RANGE80% OF RANGE

L: $57$190.27H: $224

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 9 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 18 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B-RQD 28 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on RVMD

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (45)

-28.6% ROIC with 42.0% gross margin and -2.24% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (80)

Altman-Z 26.00 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (50)

18/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like RVMD

✓Clean SEC annual filing review with no major hidden accounting time-bombs.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RVMD)

✓Walkthrough of RVMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RVMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +28.65%📐 HORIZONTAL RANGE

2026-11-01O $188.7H $190.3L $188.7C $190.3VOL 1.32M

RES: $202.7SUP: $175.9SMA50: $198.8SMA200: $156.4

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RVMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RVMD Butterfly Map → + Track RVMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

26.2%/yr Implied 5Y Growth

vs. +15.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RVMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RVMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RVMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RVMD)

Health Care Rank #126 of 188 ⚔️ BIIB vs RVMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RVMD vs. BIIB, ARGX, BNTX, MRNA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (26 Tracked Issuers)

Across 188 tracked Health Care securities in the Roarable RQD universe, Revolution Medicines Inc. (RVMD) ranks #126 by composite RQD confidence (55/100, grade D+) and #47 by equity capitalization ($40.78B). Within this direct 5-issuer industry benchmark cohort, BIIB leads on earnings valuation at 28.5x trailing P/E, while ARGX leads on capital efficiency and profitability with 9.9% ROIC and — gross margin. BIIB currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with RVMD at 55/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RVMD ACTIVE Revolution Medicines Inc.	D+	55/100	—	—	-28.6%	+0.82%	$40.78B	Benchmark Subject
BIIB Biogen Inc.	B	74/100	28.5x	75.7%	6.4%	+2.30%	$36.90B	/biib-vs-rvmd →
ARGX argenx SE	C	63/100	32.8x	—	9.9%	+0.68%	$55.72B	/argx-vs-rvmd →
BNTX BioNTech SE	D+	52/100	32.8x	—	9.9%	+1.30%	$22.39B	/bntx-vs-rvmd →
MRNA Moderna Inc.	C-	60/100	—	55.3%	-34.1%	+4.01%	$88.93B	/mrna-vs-rvmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001628171

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Revolution Medicines Inc. (RVMD) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$1.13B, operating cash flow of -$897.7M, and free cash flow of -$913.7M (-60.9% YoY). On the balance sheet, RVMD closed FY2025 with $2.35B in total assets against $325.4M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$1.13B	-$897.7M	-$913.7M	$2.35B	$325.4M
FY2024 (FY)	2024-12-31	$0	-$600.0M	-$557.4M	-$567.7M	$2.56B	$131.9M
FY2023 (FY)	2023-12-31	$11.6M	-$436.0M	-$350.6M	-$351.1M	$22.43B	$5.25B

3. RVMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RVMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Revolution Medicines Inc. (NASDAQ: RVMD) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $190.27 (+0.82% 1D, market cap $40.78B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 5/20. Across 188 tracked Health Care issuers, RVMD ranks #126 in composite RQD confidence.

How does RVMD compare to BIIB and ARGX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), RVMD carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.6%. By comparison, BIIB (Biogen Inc.) holds a B grade (74/100 RQD, P/E 28.5x, ROIC 6.4%, cap $36.90B) and ARGX (argenx SE) posts a C grade (63/100 RQD, P/E 32.8x, ROIC 9.9%, cap $55.72B). Among the 5-stock peer group, BIIB leads on earnings multiple (28.5x) while ARGX leads on capital efficiency (9.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RVMD?

Per RVMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001628171), Revolution Medicines Inc. generated $0 in revenue, -$1.13B in net income, and -$913.7M in free cash flow against $2.35B in total assets and $325.4M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RVMD trading relative to its 50-day, 200-day, and 52-week technical levels?

RVMD last traded at $190.27 (+0.82% on volume of 1,324,234 shares), positioning the stock -4.31% below its 50-day simple moving average ($198.84) and +21.68% above its 200-day simple moving average ($156.37). Across its 52-week range of $56.66 to $224.31, RVMD sits at the 79.7% percentile with a 14-day RSI of 47.8 (NEUTRAL RANGE) and an implied next-earnings move of ±10.1% ($171.05 to $209.49).

RVMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell RVMD stock right now?

Revolution Medicines Inc. (RVMD) currently earns a Roarable Rating of D+ (Sell — SELL) with 55/100 RQD Confidence. Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.

What is RVMD's 12-month price target and RQD AI Jury consensus?

RVMD's 12-month base price target is $187.7 (range $146.41 to $235.53), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: RVMD RQD Cockpit RVMD 12M Forecast RVMD Earnings & Move RVMD Dividends & DRIP RVMD Insiders & 13F RVMD Whale Options RVMD Profit Sankey RVMD News & Why